Figure 1.

A, Change in mean five‐dimension European Quality of Life questionnaire (EQ‐5D) index score. B, Change in mean EQ‐5D visual analogue scale (VAS) score. Estimated data. Patients with an observed value contributed to the analysis. Patients who died were given a value of zero at the first planned visit after death. Change from baseline to 36‐month assessment was analysed using a linear mixed model, accounting for repeated measures within patients. Interaction between visit and treatment, sex, region and antidiabetic therapy, respectively, at baseline are included as factors, and interaction between visit and baseline EQ‐5D index/VAS score and age at baseline, respectively, are included as covariates. EOT, end of trial